BioTE hormone pellet therapy is a pioneer in helping people feel better. Like everything, it comes with its set of repercussions and price tags. If you are considering BioTE hormone pellet therapy, it’s time to spit out some facts.
BioTE uses compounded bioidentical hormone pellets, each about the size of a grain of rice, inserted just beneath the skin in the upper buttocks.
The pellets release estrogen and testosterone gradually over three to six months, aiming to keep hormone levels steady without the daily rhythm of pills, creams, or patches.
Patient interest in this approach has grown significantly. There are biote supplement reviews across online forums and health communities that reflect a wide range of experiences, from life-changing relief to frustrating complications.
The reality, as with most medical treatments, falls somewhere in the middle. Understanding the actual risk profile helps you go into any consultation with the right questions.
Physical and Procedural Risks to Know Before Starting
Because BioTE involves an incision and a foreign object placed under your skin, the procedure itself carries inherent risks. Bleeding at the insertion site can occur, though it typically stays minor.
Infection is also possible, and while rare with proper technique and sterile conditions, it requires prompt treatment when it does develop.
Cellulitis is a skin infection that affects the surrounding tissue. It appears in FDA adverse event data tied to compounded hormone pellets and warrants awareness.
Another most mentioned procedural complication is pellet extrusion. Usually, it happens when the body pushes the pellet out toward the skin surface rather than absorbing it. Extrusion rates vary depending on technique and the specific compounding formula used.
A 2024 paper published directly on the Biote website by physicians Doreen Saltiel and Ross McQuivey addressed the growing practice of adding triamcinolone, a synthetic corticosteroid, to pellets to reduce extrusion risk.
Their review found that the long-term systemic use of triamcinolone carries well-documented risks of its own. The risks include adrenal suppression, osteoporosis, elevated blood pressure, cataracts, and increased infection risk.
They concluded that combination pellets should be used only in select cases and with caution, as the safety data does not yet support routine use.
Beyond the insertion site, some patients experience hormonal fluctuation symptoms in the weeks after their first pellet.
Your body adjusts to new hormone levels, and that transition can temporarily bring back the very symptoms you sought treatment for, including fatigue, mood changes, and disrupted sleep.
Bioidentical Hormones and Cancer Risk: What the Research Shows
The cancer conversation sits at the center of most serious discussions about BioTE, and it is a conversation that deserves real honesty rather than reassurance alone.
The bioidentical hormones and cancer risk question has no simple answer, but the research does give us important guidance.
The FDA drew sharp attention to this issue in 2019 when agency investigators, during a BioTE Medical inspection, uncovered 4,202 adverse events that had never been reported to the agency.
The adverse event data suggested possible associations between compounded hormone pellets and endometrial cancer, prostate cancer, strokes, heart attacks, and deep vein thrombosis.
That disclosure, published directly on FDA.gov, created significant concern in the clinical community and raised questions that have driven much of the subsequent research.
2024 Case
On the cancer question specifically, a 2024 case-cohort analysis was published in the journal Cancer Causes and Control. It includes data from the Melbourne Collaborative Cohort Study, which found that progesterone, estrogens, and androgens likely increase postmenopausal estrogen receptor-positive breast cancer risk.
That analysis looked at over 1,200 women and found a measurable increased risk associated with total estradiol, free estradiol, progesterone, and total testosterone.
A 2024 systematic review and meta-analysis published in Frontiers in Endocrinology. It analyzed 21 cohort studies with more than 4.5 million participants and 30 case-control studies. The study found that hormone replacement therapy users carry a pooled breast cancer risk approximately 20 percent higher than non-users in cohort studies.
Bioidentical hormones and cancer risk become more complicated when the delivery method enters the discussion.
The American Cancer Society notes at cancer.org that compounded bioidentical hormones are often marketed as being more natural and therefore safer. Still, the FDA does not test these products for quality or safety.
No long-term clinical trials specifically demonstrate that compounded bioidentical pellets carry a lower cancer risk than conventionally approved hormone therapies.
The American Cancer Society recommends assuming they carry at least the same risk profile as other forms of menopausal hormone therapy.
2025 U-turn
There is some encouraging news in the 2025 regulatory landscape. The FDA removed the black box warning from many hormone replacement therapy products in November 2025, as reported by breastcancer.org.
It cites the growing evidence that the benefits of hormone therapy outweigh the risks for many women, particularly those who start within 10 years of menopause or before age 60. That shift reflects the more nuanced picture emerging from recent research.
However, the nuance matters: risk is not eliminated; it is contextualized. Individual factors, including personal and family cancer history, duration of therapy, dosage level, and the specific hormones involved, all affect the actual risk level for any given patient.
Biote pellets weight loss reviews also reflect a pattern worth flagging. Some patients pursue BioTE primarily for weight management and metabolic improvements.
Making a Fully Informed Decision About BioTE
BioTE works well for some patients and poorly for others, and the difference often comes down to provider quality, appropriate dosing, and whether the patient had realistic expectations going in.
Biote supplement reviews from satisfied patients consistently describe improved energy, better sleep, reduced anxiety, and stronger libido. Negative BioTE supplement reviews tend to cluster around overdosing symptoms, poor follow-up, and difficulty getting dosage corrections.
Anyone considering BioTE should bring a specific set of questions to their consultation. Firstly, ask about the provider’s experience and how many pellet insertions they have performed.
Ask how they determine the starting dosage and how quickly they respond if hormone levels come back too high.
Also, ask about their monitoring protocol between insertions. Ask directly about the bioidentical hormones and cancer risk literature, particularly if you carry a personal or family history of hormone-sensitive cancers. And understand fully what BioTE pellets cost will look like across a full year, not just the first insertion.
The team at Hamilton Wellness approaches hormone therapy with exactly this kind of careful, individualized framework. They take the time to review your full health history, explain the risk picture honestly, and build a monitoring plan designed to keep your levels within a safe and effective range.
You can learn more about their approach to bioidentical hormone therapy at hamiltonwellness.org.
Side effects of the BioTE pellet in females
Common side effects of BioTE pellets in females include acne, facial hair growth, mood swings, weight changes, and irregular bleeding, while rare but serious risks involve blood clots and infection at the insertion site.
Why are hormone pellets not recommended?
Major medical organizations like ACOG do not routinely recommend hormone pellets because they lack FDA approval for menopausal symptoms, carry risks of dosing inconsistency and infection at the insertion site, and cannot be removed if side effects occur, leaving patients exposed to hormones for months until the pellet dissolves.
Is BioTE hormone replacement safe?
BioTE hormone replacement can be safe for some patients under proper medical supervision, but it carries risks, including dosing inconsistency, inability to remove pellets if side effects occur, and limited long-term safety data, so it requires careful evaluation by a qualified provider.